Goodwill and Intangible Assets (Additional Information) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	May 31, 2023	Aug. 22, 2022	Jul. 11, 2022
Goodwill [Line Items]
Goodwill	$ 17,905		$ 17,905		$ 17,905
Amortization expense	6,440	$ 4,958	12,880	$ 8,763
Goodwill, impairment losses	0	0	0	0
Collaboration agreement
Goodwill [Line Items]
Amortization expense	6,400	5,000	12,900	8,800
In-process research and development
Goodwill [Line Items]
Amortization expense	0	$ 0	0	$ 0
Acquired Finite-Lived Intangible Asset, Residual Value						$ 2,600
In-process research and development | XACDURO
Goodwill [Line Items]
Intangible assets pertain to product rights and developed technologies						$ 68,700
La Jolla Pharmaceutical Company
Goodwill [Line Items]
Goodwill							$ 6,400
Future amortization expense, remainder of 2024	12,900		12,900
Future amortization expense, 2025	25,800		25,800
Future amortization expense, 2026	25,800		25,800
Future amortization expense, 2027	25,800		25,800
Future amortization expense, 2028	25,800		25,800
Future amortization expense, thereafter	98,700		98,700
Intangible assets pertain to product rights and developed technologies	151,000		151,000
Entasis Therapeutics Holdings Inc
Goodwill [Line Items]
Goodwill								$ 11,500
Intangible assets pertain to product rights and developed technologies	106,700		106,700
Entasis Therapeutics Holdings Inc | Collaboration agreement
Goodwill [Line Items]
Intangible assets pertain to product rights and developed technologies	35,400		35,400
Entasis Therapeutics Holdings Inc | In-process research and development
Goodwill [Line Items]
Intangible assets pertain to product rights and developed technologies	$ 71,300		$ 71,300